Table 2. Primary outcome: Early Fungicidal Activity over the first 2 weeks following randomization (log10 colony-forming units (CFU)/ml/day).
| Treatment Arm | ||||||
|---|---|---|---|---|---|---|
| Analysis populations | Total | Tamoxifen | Total | Standard of Care | Difference in change | p-value† |
| N | Change/day (95% CI*) | N | Change/day (95% CI*) | (95% CI*) | ||
| Intention-to-treat | 24 | −0.49 (−0.62,–0.37) |
26 | −0.48 (−0.61,–0.37) |
−0.005 (−0.16, 0.15) |
0.95 |
| Per-protocol | 23 | −0.48 (−0.61,–0.36) |
25 | −0.48 (−0.61,–0.37) |
0.004 (−0.17, 0.17) |
0.96 |
| HIV-infected patients | 19 | −0.49 (−0.65,–0.37) |
21 | −0.42 (−0.55,–0.31) |
−0.072 (−0.25, 0.10) |
0.41 |
| HIV-uninfected patients | 5 | −0.42 (−0.74,–0.21) |
5 | −0.57 (−0.93,–0.33) |
0.16 (−0.18, 0.55) |
0.37 |
*95% CI corresponds to Bayesian 95% credible intervals.
†p-value refers to crude ‘Wald-type’ tests of the mean estimate divided by its standard deviation of the Monte Carlo Markov chain sampling of coefficients derived from the joint model.